| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
EHP Inc is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Richman Root Delaney MD is a Waterford, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wellnet Healthcare is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
lww vision care group is a Ambler, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.